Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAD | Q92934 | 18/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 14/20 | 0.39 |
| ▸ | BCL2 | P10415 | 12/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.36 |
| ▸ | PMAIP1 | Q13794 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25786245 | 0.96 | BAD (0.39) | BADBCL2L1BCL2MCL1PMAIP1 | |
| SCHEMBL25786229 | 0.87 | BAD (0.42) | BADBCL2L1BCL2MCL1PMAIP1 | |
| SCHEMBL25786248 | 0.86 | BAD (0.41) | BADBCL2L1BCL2MCL1PMAIP1 | |
| SCHEMBL25786244 | 0.86 | BAD (0.33) | BADBCL2L1BCL2MCL1PMAIP1 | |
| SCHEMBL25786224 | 0.86 | BAD (0.43) | BADBCL2L1BCL2MCL1PMAIP1 | |
| SCHEMBL25786253 | 0.85 | BAD (0.40) | BADBCL2L1BCL2MCL1PMAIP1 | |
| SCHEMBL25786252 | 0.82 | BAD (0.42) | BADBCL2L1BCL2MCL1PMAIP1 | |
| SCHEMBL25786617 | 0.82 | BAD (0.45) | BADBCL2L1BCL2MCL1PMAIP1 | |
| SCHEMBL25786250 | 0.81 | BAD (0.42) | BADBCL2L1BCL2MCL1PMAIP1 | |
| SCHEMBL25786222 | 0.80 | BAD (0.41) | BADBCL2L1BCL2MCL1PMAIP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | MCL1, BCL2A1, BCL2L1 | BAD 20/4885BCL2L1 3/4885BCL2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.